法国Hybrigenics 
法国巴斯德研究所与法国Hybrigenics公司新近合作完成世界上第一张幽门螺杆菌蛋白质的相互作用图

Hybrigenics is a biotechnology and pharmaceutical company focusing its internal R&D programs on innovative target and therapeutics against cancer and commercializing its high throughput technology and bioinformatics platforms to identify, validate and inhibit protein interactions.
Hybrigenics’ most advanced development program is based on inecalcitol, a vitamin D analogue, for prostate cancer in combination with current reference treatments, for improved efficacy and better tolerance.
Hybrigenics’ research program explores the role of Ubiquitin-Specific Proteases (USPs) in the degradation of onco-proteins, and the use of proprietary USP inhibitors against various cancer types.
Hybrigenics offers to researchers from all life sciences an access to its ISO 9001-certified Yeast-Two Hybrid (Y2H) high throughput screening platform, to its sophisticated bioinformatics set of tools and extensive database, and to its chemical library and high throughput small molecule screening platform, as fee-for-service activities.
Hybrigenics is organized in two operational units: Hybrigenics Pharma for the internal R&D programs and Hybrigenics Services for the commercial business, coordinated with economies of scale by a common corporate, financial and administrative management. The core link among all Hybrigenics activities is trust in science for life.